Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
444 participants
Study Classification
OBSERVATIONAL
Study Start Date
2019-07-30
Study Completion Date
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Northern New England has among the highest rates of opioid dependence in the U.S, with prevalence highest and growing among those of between the ages of 18-35 years. This region also has among the highest rates of opioid-related deaths in the U.S., with a disproportionate high rate among pregnant women with opioid use disorder. In northern New England (Maine, New Hampshire, \& Vermont), 5-8% of newborns have mothers with an opioid use disorder (OUD), greatly increasing the risk of poor outcomes, including preterm birth and long hospitalization for neonatal withdrawal and other newborn complications. For pregnant women with OUD, medication assisted treatment (MAT) significantly reduces these risks. However, it is sometimes difficult for pregnant women to find MAT providers. As a result, many maternity care providers have begun to prescribe MAT in their own practices. Other practices have maintained the longstanding evidence-based standard of care, referral of patients with OUD to specialty MAT treatment program. Most pregnant women with OUD have other psychosocial needs, ranging from lack of housing and untreated mental health conditions, to need for parenting education and support. There is variability among practices in terms of types of other services provided to patients, whether the practice has integrated MAT or relies on referral. Although pregnancy is a time when women are highly motivated to start MAT, many women are also likely to discontinue MAT postpartum due to loss of insurance coverage, difficulty transitioning to another provider, loss of motivation for treatment, or competing demands on time and resources as a new parent.
The challenge for patients, providers, and other stakeholders is to understand the relative advantage of the two MAT models (receiving MAT as part of maternity care or at a specialty program) for improving key outcomes for baby \& mother. A second challenge is to understand the relative contributions of onsite services such as mental health care, care coordination, \& parenting education to improved outcomes. This question is important to patients \& families who may have a choice of where they receive their maternity care. It is even more important in rural areas, such as northern New England, where obstetric practices \& specialty care services are limited. Patients, providers \& other stakeholders need guidance in choosing the optimal models for building new programs to provide maternity care for women with OUD.
The challenge for patients, providers, and other stakeholders is to understand the relative advantage of the two MAT models (receiving MAT as part of maternity care or at a specialty program) for improving key outcomes for baby \& mother. A second challenge is to understand the relative contributions of onsite services such as mental health care, care coordination, \& parenting education to improved outcomes. This question is important to patients \& families who may have a choice of where they receive their maternity care. It is even more important in rural areas, such as northern New England, where obstetric practices \& specialty care services are limited. Patients, providers \& other stakeholders need guidance in choosing the optimal models for building new programs to provide maternity care for women with OUD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions
NCT04049799
Opioid-use Disorder
Opioid Withdrawal
Neonatal Abstinence Syndrome
+1 more
COMPLETED
Improving Effective Contraceptive Use Among Opioid-maintained Women
NCT01425060
Contraceptive Usage
Opioid Dependence
COMPLETED
PHASE1
mHealth to Help Pregnant and Postpartum Women in Recovery for Opioid Use Disorder
NCT06701123
Opioid Use Disorders
COMPLETED
EARLY_PHASE1
Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care
NCT01751789
Illicit Opioid Drug Use
COMPLETED
NA
Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People
NCT06496230
Opioid Use Disorder
Pregnancy Related
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Northern New England has among the highest rates of opioid dependence in the U.S, with prevalence highest and growing among those aged 18-35 years. Regional rates of perinatal opioid use disorders (OUD) reflect this public health crisis; Northern New England region has the highest incidence of opioid-related births in the nation. Perinatal opioid use disorders impact 5-8% of pregnancies in Maine, New Hampshire, and Vermont, three states that have been severely impacted by the current opioid epidemic. Consequences of inadequately treated OUD include premature delivery and other perinatal complications, prolonged newborn hospitalization for neonatal abstinence (NAS), and maternal morbidity and mortality from infectious disease and overdose. In 2013, costs associated with NAS treatment in the U.S. reached $1.5 billion. The epidemic has grown multifold since 2013.
Medication assisted treatment (MAT) with either methadone or buprenorphine is the recommended standard of care during pregnancy. Professionals, including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics, the Society for Maternal-Fetal Medicine, and the American Society for Addiction Medicine, have called to adopt care models that promote early identification and treatment for pregnant women with OUD. Referral to specialty programs for MAT has been the accepted standard of care, with demonstrated safety for women and their infants. However, in response to the escalating opioid crisis, the ACOG began offering buprenorphine training programs to its members. Consequently, a number of maternity care practices throughout Northern New England now provide integrated MAT services. But even where such integrated programs exist, questions persist on the optimal care model for providing MAT to pregnant women with OUD.
There are patient- and provider- factors associated with variability in effectiveness of what MAT model works best for whom. For women, advantages of buprenorphine over methadone include a lower risk of overdose, fewer drug interactions, the accessibility of office-based treatment delivery in the context of maternity care and demonstrated shorter NAS course. The disadvantages of buprenorphine relative to methadone include potential hepatic dysfunction, lack of long-term data on consequences of fetal exposure for infants, potential limited efficacy in patients with high addiction severity, requirement of moderate withdrawal symptoms prior to initiation to avoid iatrogenic withdrawal, and an increased risk of diversion (i.e., sharing or sale). Despite buprenorphine's demonstrated neonatal advantages, it is not effective for all women. The structure of methadone treatment (daily meeting) may also better align with support needs for some women. For providers, the choice of what medication-assisted approach to offer to patients is often restricted by availability and access to specialty care services.
There is limited literature comparing the effectiveness of integrated versus referral MAT care models for postpartum retention in treatment and women's experiences in these two models. In particular, women with high levels of addiction severity or co-occurring mental health conditions may have prenatal care needs from women with less complex behavioral health concerns. Studies have also not assessed the impact of maternal opioid addiction severity on newborn outcomes and maternal long-term recovery. The best neonatal outcomes will be achieved by providing the most appropriate and effective treatment for mothers.
The challenge for patients, providers, and other stakeholders is determining the optimal approach for delivering MAT during pregnancy and after delivery to improve outcomes. Currently, regional obstetrical practices provide either: (1) Integrated care, in which MAT and associated psychosocial services are delivered on site with obstetrical care, and (2) Referral-based care, in which women receive MAT and obstetrical care in separate, specialized locations. Both models have different potential advantages and disadvantages for mothers with OUD and their babies regarding access, availability, acceptability and quality of MAT, obstetrics and other needed services, and long term follow up and treatment after delivery. While pregnancy motivates women to initiate MAT, relapse to use of opioids and cessation of MAT frequently occur during the first postpartum year, placing both mother and infant at significant risk. Payers and policymakers are also seeking answers about where to invest healthcare resources to increase access to treatment for pregnant women, especially in the current opioid crisis. A disproportionate number of women with OUD are insured through the Medicaid system; Medicaid policy affects women's access to a wide range of services, from reimbursement for same-day services or care coordination, to whether a woman continues to be eligible for benefits after delivery.
Study Aims: This study aims to answer these important patient, provider, and policy questions by comparing the real-world effectiveness of two models of MAT delivery currently in clinical use in Maine, New Hampshire, and Vermont with respect to patient experience of care and perinatal, neonatal, and longer-term substance use treatment outcomes.
Two main Comparative Effectiveness Research (CER) Patient-Centered Outcomes Research Institute (PCORI) priority questions will be addressed:
1. Do clinical and patient-reported outcomes for pregnant and parenting women differ between integrated and referral-based MAT practice models?
2. Within models, which psychosocial services are most associated with MAT continuation, and for which groups of patients?
To answer these questions, the following specific aims will be addressed:
Aim 1 (Clinical Outcomes). To use clinical record data to evaluate the comparative effectiveness of Integrated and Referral-Based MAT care models on maternal and neonatal outcomes.
Aim 2 (Patient-reported Outcomes). To use patient reported data to evaluate the comparative effectiveness of Integrated and Referral -Based care models on patient-centered outcomes.
Aim 3 (Heterogeneity of Effects). To examine differences in treatment retention within condition by subgroups of patients based on (1) psychiatric comorbidity, (2) type of medication used for MAT and (3) addiction severity.
Aim 4 (Specification of Services). To determine which services (psychosocial services, care coordination, parenting education) are associated with better maternal and neonatal outcomes.
Aim 5 (Provider). To explore how provider attitudes about MAT and care of patients with OUD vary by care model and are associated with maternal outcomes.
Study Description: This study will collaboratively engage 21 practices providing maternity care across Northern New England, with examples of both integrated care and referral-based models. The study population is pregnant women who receive prenatal care from any of these practices and who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for an opioid use disorder. A cluster-based, prospective observational mixed-methods design will be used to compare outcomes for pregnant women with opioid use disorder receiving prenatal care in obstetric practices that offer MAT through one of two delivery models: Integrated or Referral-based. Clinical records data (n=2000) from pregnant women with OUD receiving prenatal care at a partner practice will be used to examine Aim 1. Aim 2 will be addressed with a patient-report subsample cohort (n=532) recruited in the 3rd trimester of care and followed to 6 months postpartum. Aim 3 will use both kinds of data to explore heterogeneity of treatment effects. For Aim 4, practice-level data will be collected yearly to evaluate services provided across Integrated and Referral-based practices. In Aim 5, survey and qualitative interviews with providers will lend perspective on facilitators and barriers to MAT in both Integrated and Referral-based practice settings. The analytic strategy will account for clustering and patient baseline differences to compare outcomes across assessment points. Whether the effect of treatment type differs according to psychiatric status, type of MAT patients access, or addiction severity will also be tested. Analysis of qualitative data will inform our interpretation of quantitative results and enhance our understanding of patient experience, as well as barriers and facilitators to receiving care within these care models. Patient representatives, practice-partners, state and regional stakeholders, and scientific advisors will actively guide all stages of this study and dissemination of results to relevant partner networks.
Medication assisted treatment (MAT) with either methadone or buprenorphine is the recommended standard of care during pregnancy. Professionals, including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics, the Society for Maternal-Fetal Medicine, and the American Society for Addiction Medicine, have called to adopt care models that promote early identification and treatment for pregnant women with OUD. Referral to specialty programs for MAT has been the accepted standard of care, with demonstrated safety for women and their infants. However, in response to the escalating opioid crisis, the ACOG began offering buprenorphine training programs to its members. Consequently, a number of maternity care practices throughout Northern New England now provide integrated MAT services. But even where such integrated programs exist, questions persist on the optimal care model for providing MAT to pregnant women with OUD.
There are patient- and provider- factors associated with variability in effectiveness of what MAT model works best for whom. For women, advantages of buprenorphine over methadone include a lower risk of overdose, fewer drug interactions, the accessibility of office-based treatment delivery in the context of maternity care and demonstrated shorter NAS course. The disadvantages of buprenorphine relative to methadone include potential hepatic dysfunction, lack of long-term data on consequences of fetal exposure for infants, potential limited efficacy in patients with high addiction severity, requirement of moderate withdrawal symptoms prior to initiation to avoid iatrogenic withdrawal, and an increased risk of diversion (i.e., sharing or sale). Despite buprenorphine's demonstrated neonatal advantages, it is not effective for all women. The structure of methadone treatment (daily meeting) may also better align with support needs for some women. For providers, the choice of what medication-assisted approach to offer to patients is often restricted by availability and access to specialty care services.
There is limited literature comparing the effectiveness of integrated versus referral MAT care models for postpartum retention in treatment and women's experiences in these two models. In particular, women with high levels of addiction severity or co-occurring mental health conditions may have prenatal care needs from women with less complex behavioral health concerns. Studies have also not assessed the impact of maternal opioid addiction severity on newborn outcomes and maternal long-term recovery. The best neonatal outcomes will be achieved by providing the most appropriate and effective treatment for mothers.
The challenge for patients, providers, and other stakeholders is determining the optimal approach for delivering MAT during pregnancy and after delivery to improve outcomes. Currently, regional obstetrical practices provide either: (1) Integrated care, in which MAT and associated psychosocial services are delivered on site with obstetrical care, and (2) Referral-based care, in which women receive MAT and obstetrical care in separate, specialized locations. Both models have different potential advantages and disadvantages for mothers with OUD and their babies regarding access, availability, acceptability and quality of MAT, obstetrics and other needed services, and long term follow up and treatment after delivery. While pregnancy motivates women to initiate MAT, relapse to use of opioids and cessation of MAT frequently occur during the first postpartum year, placing both mother and infant at significant risk. Payers and policymakers are also seeking answers about where to invest healthcare resources to increase access to treatment for pregnant women, especially in the current opioid crisis. A disproportionate number of women with OUD are insured through the Medicaid system; Medicaid policy affects women's access to a wide range of services, from reimbursement for same-day services or care coordination, to whether a woman continues to be eligible for benefits after delivery.
Study Aims: This study aims to answer these important patient, provider, and policy questions by comparing the real-world effectiveness of two models of MAT delivery currently in clinical use in Maine, New Hampshire, and Vermont with respect to patient experience of care and perinatal, neonatal, and longer-term substance use treatment outcomes.
Two main Comparative Effectiveness Research (CER) Patient-Centered Outcomes Research Institute (PCORI) priority questions will be addressed:
1. Do clinical and patient-reported outcomes for pregnant and parenting women differ between integrated and referral-based MAT practice models?
2. Within models, which psychosocial services are most associated with MAT continuation, and for which groups of patients?
To answer these questions, the following specific aims will be addressed:
Aim 1 (Clinical Outcomes). To use clinical record data to evaluate the comparative effectiveness of Integrated and Referral-Based MAT care models on maternal and neonatal outcomes.
Aim 2 (Patient-reported Outcomes). To use patient reported data to evaluate the comparative effectiveness of Integrated and Referral -Based care models on patient-centered outcomes.
Aim 3 (Heterogeneity of Effects). To examine differences in treatment retention within condition by subgroups of patients based on (1) psychiatric comorbidity, (2) type of medication used for MAT and (3) addiction severity.
Aim 4 (Specification of Services). To determine which services (psychosocial services, care coordination, parenting education) are associated with better maternal and neonatal outcomes.
Aim 5 (Provider). To explore how provider attitudes about MAT and care of patients with OUD vary by care model and are associated with maternal outcomes.
Study Description: This study will collaboratively engage 21 practices providing maternity care across Northern New England, with examples of both integrated care and referral-based models. The study population is pregnant women who receive prenatal care from any of these practices and who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for an opioid use disorder. A cluster-based, prospective observational mixed-methods design will be used to compare outcomes for pregnant women with opioid use disorder receiving prenatal care in obstetric practices that offer MAT through one of two delivery models: Integrated or Referral-based. Clinical records data (n=2000) from pregnant women with OUD receiving prenatal care at a partner practice will be used to examine Aim 1. Aim 2 will be addressed with a patient-report subsample cohort (n=532) recruited in the 3rd trimester of care and followed to 6 months postpartum. Aim 3 will use both kinds of data to explore heterogeneity of treatment effects. For Aim 4, practice-level data will be collected yearly to evaluate services provided across Integrated and Referral-based practices. In Aim 5, survey and qualitative interviews with providers will lend perspective on facilitators and barriers to MAT in both Integrated and Referral-based practice settings. The analytic strategy will account for clustering and patient baseline differences to compare outcomes across assessment points. Whether the effect of treatment type differs according to psychiatric status, type of MAT patients access, or addiction severity will also be tested. Analysis of qualitative data will inform our interpretation of quantitative results and enhance our understanding of patient experience, as well as barriers and facilitators to receiving care within these care models. Patient representatives, practice-partners, state and regional stakeholders, and scientific advisors will actively guide all stages of this study and dissemination of results to relevant partner networks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Opioid-Related Disorders
NAS
Substance Use Disorders
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Integrated Care
This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
Observational Study
Intervention Type
OTHER
No intervention will be administered.
Referral-Based Care
This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
Observational Study
Intervention Type
OTHER
No intervention will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational Study
No intervention will be administered.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 16 year and older,
* Identified opioid use disorder,
* Receiving prenatal care for current pregnancy at partner practice,
* Clinic-recorded diagnosis of opioid use disorder,
* Willing and able to provide informed consent.
* Identified opioid use disorder,
* Receiving prenatal care for current pregnancy at partner practice,
* Clinic-recorded diagnosis of opioid use disorder,
* Willing and able to provide informed consent.
Exclusion Criteria
* Ward of the State
Minimum Eligible Age
16 Years
Maximum Eligible Age
50 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Patient-Centered Outcomes Research Institute
OTHER
Sponsor Role
collaborator
Trustees of Dartmouth College
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sarah E. Lord
Associate Professor of Psychiatry, Biomedical Data Science and Pediatrics; Director, Dissemination and Implementation Core, Center for Technology and Behavioral Health
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah E Lord, PhD
Role: PRINCIPAL_INVESTIGATOR
Dartmouth College
Daisy Goodman, DNP, MPH
Role: PRINCIPAL_INVESTIGATOR
Dartmouth-Hitchcock Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maine General Hospital
Augusta, Maine, United States
Site Status
Eastern Maine Medical Center/Northern Light
Bangor, Maine, United States
Site Status
Dartmouth Hitchcock Keene/Cheshire Medical Center OB-GYN
Keene, New Hampshire, United States
Site Status
Dartmouth-Hitchcock Medical Center-OB/GYN
Lebanon, New Hampshire, United States
Site Status
Dartmouth Hitchcock Addiction Treatment, Moms in Recovery
Lebanon, New Hampshire, United States
Site Status
Dartmouth Hitchcock Bedford/Manchester
Manchester, New Hampshire, United States
Site Status
Dartmouth Hitchcock Nashua OB-GYN
Nashua, New Hampshire, United States
Site Status
Southwestern Vermont Medical Center OB-GYN
Bennington, Vermont, United States
Site Status
Central Vermont Medical Center
Berlin Corners, Vermont, United States
Site Status
Brattleboro Memorial Hospital OB-GYN
Brattleboro, Vermont, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep. 2016 Aug 12;65(31):799-802. doi: 10.15585/mmwr.mm6531a2.
Reference Type
BACKGROUND
Patrick SW, Schiff DM; COMMITTEE ON SUBSTANCE USE AND PREVENTION. A Public Health Response to Opioid Use in Pregnancy. Pediatrics. 2017 Mar;139(3):e20164070. doi: 10.1542/peds.2016-4070. Epub 2017 Feb 20.
Reference Type
BACKGROUND
Jones HE. Treating opioid use disorders during pregnancy: historical, current, and future directions. Subst Abus. 2013;34(2):89-91. doi: 10.1080/08897077.2012.752779.
Reference Type
BACKGROUND
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359.
Reference Type
BACKGROUND
Reddy UM, Davis JM, Ren Z, Greene MF; Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers. Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol. 2017 Jul;130(1):10-28. doi: 10.1097/AOG.0000000000002054.
Reference Type
BACKGROUND
Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015 Aug;105(8):e55-63. doi: 10.2105/AJPH.2015.302664. Epub 2015 Jun 11.
Reference Type
BACKGROUND
Milligan K, Niccols A, Sword W, Thabane L, Henderson J, Smith A, Liu J. Maternal substance use and integrated treatment programs for women with substance abuse issues and their children: a meta-analysis. Subst Abuse Treat Prev Policy. 2010 Sep 1;5:21. doi: 10.1186/1747-597X-5-21.
Reference Type
BACKGROUND
Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. 2015 Apr 1;149:225-31. doi: 10.1016/j.drugalcdep.2015.02.012. Epub 2015 Feb 19.
Reference Type
BACKGROUND
Flavin J. (2002) A Glass Half Full? Harm reduction amongpregnant women who use cocaine. Journal of Drug Issues, 32(3):973-998. https://journals.sagepub.com/doi/10.1177/002204260203200315
Reference Type
BACKGROUND
Roberts SC, Nuru-Jeter A. Women's perspectives on screening for alcohol and drug use in prenatal care. Womens Health Issues. 2010 May-Jun;20(3):193-200. doi: 10.1016/j.whi.2010.02.003.
Reference Type
BACKGROUND
Wright TE, Schuetter R, Fombonne E, Stephenson J, Haning WF 3rd. Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. Harm Reduct J. 2012 Jan 19;9:5. doi: 10.1186/1477-7517-9-5.
Reference Type
BACKGROUND
Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, Fischer G. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012 Nov;107 Suppl 1(0 1):5-27. doi: 10.1111/j.1360-0443.2012.04035.x.
Reference Type
BACKGROUND
Roberts SC, Pies C. Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care. Matern Child Health J. 2011 Apr;15(3):333-41. doi: 10.1007/s10995-010-0594-7.
Reference Type
BACKGROUND
Terplan M, Kennedy-Hendricks A, Chisolm MS. Prenatal Substance Use: Exploring Assumptions of Maternal Unfitness. Subst Abuse. 2015 Sep 20;9(Suppl 2):1-4. doi: 10.4137/SART.S23328. eCollection 2015.
Reference Type
BACKGROUND
Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014 Feb 1;65(2):158-70. doi: 10.1176/appi.ps.201300256.
Reference Type
BACKGROUND
Saloner B, Karthikeyan S. Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. JAMA. 2015 Oct 13;314(14):1515-7. doi: 10.1001/jama.2015.10345. No abstract available.
Reference Type
BACKGROUND
Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008 Mar-Apr;17(2):116-20. doi: 10.1080/10550490701860971.
Reference Type
BACKGROUND
Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Ann Intern Med. 2017 Feb 21;166(4):268-278. doi: 10.7326/M16-2149. Epub 2016 Dec 6.
Reference Type
BACKGROUND
Boyd SC, Marcellus L. (2007) With child: substance use during pregnancy, a woman-centered approach. Halifax [N.S.]: Fernwood Pub.
Reference Type
BACKGROUND
Hall JL, van Teijlingen ER. A qualitative study of an integrated maternity, drugs and social care service for drug-using women. BMC Pregnancy Childbirth. 2006 Jun 13;6:19. doi: 10.1186/1471-2393-6-19.
Reference Type
BACKGROUND
Lefebvre L, Midmer D, Boyd JA, Ordean A, Graves L, Kahan M, Pantea L. Participant perception of an integrated program for substance abuse in pregnancy. J Obstet Gynecol Neonatal Nurs. 2010 Jan-Feb;39(1):46-52. doi: 10.1111/j.1552-6909.2009.01083.x.
Reference Type
BACKGROUND
Corse SJ, McHugh MK, Gordon SM. Enhancing provider effectiveness in treating pregnant women with addictions. J Subst Abuse Treat. 1995 Jan-Feb;12(1):3-12.
Reference Type
BACKGROUND
Armstrong MA, Gonzales Osejo V, Lieberman L, Carpenter DM, Pantoja PM, Escobar GJ. Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. J Perinatol. 2003 Jan;23(1):3-9. doi: 10.1038/sj.jp.7210847.
Reference Type
BACKGROUND
Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol. 2008 Sep;28(9):597-603. doi: 10.1038/jp.2008.70. Epub 2008 Jun 26.
Reference Type
BACKGROUND
Meyer M, Phillips J. Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas. Prev Med. 2015 Nov;80:18-22. doi: 10.1016/j.ypmed.2015.07.015. Epub 2015 Jul 26.
Reference Type
BACKGROUND
Ordean A, Kahan M, Graves L, Abrahams R, Boyajian T. Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study. Can Fam Physician. 2013 Oct;59(10):e462-9.
Reference Type
BACKGROUND
Jansson LM, Velez ML. Infants of drug-dependent mothers. Pediatr Rev. 2011 Jan;32(1):5-12; quiz 12-3. doi: 10.1542/pir.32-1-5. No abstract available.
Reference Type
BACKGROUND
Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev. 2015 Apr 2;2015(4):CD006037. doi: 10.1002/14651858.CD006037.pub3.
Reference Type
BACKGROUND
Morgenstern J, Blanchard KA, McCrady BS, McVeigh KH, Morgan TJ, Pandina RJ. Effectiveness of intensive case management for substance-dependent women receiving temporary assistance for needy families. Am J Public Health. 2006 Nov;96(11):2016-23. doi: 10.2105/AJPH.2005.076380. Epub 2006 Oct 3.
Reference Type
BACKGROUND
Dowdell JA, Fenwick J, Bartu A, Sharp J. Midwives' descriptions of the postnatal experiences of women who use illicit substances: a descriptive study. Midwifery. 2009 Jun;25(3):295-306. doi: 10.1016/j.midw.2007.03.008. Epub 2007 Jul 5.
Reference Type
BACKGROUND
Tuten M, Jones HE. A partner's drug-using status impacts women's drug treatment outcome. Drug Alcohol Depend. 2003 Jun 5;70(3):327-30. doi: 10.1016/s0376-8716(03)00030-9.
Reference Type
BACKGROUND
Niccols A, Milligan K, Sword W, Thabane L, Henderson J, Smith A. Integrated programs for mothers with substance abuse issues: A systematic review of studies reporting on parenting outcomes. Harm Reduct J. 2012 Mar 19;9:14. doi: 10.1186/1477-7517-9-14.
Reference Type
BACKGROUND
Niccols A, Milligan K, Smith A, Sword W, Thabane L, Henderson J. Integrated programs for mothers with substance abuse issues and their children: a systematic review of studies reporting on child outcomes. Child Abuse Negl. 2012 Apr;36(4):308-22. doi: 10.1016/j.chiabu.2011.10.007. Epub 2012 Apr 5.
Reference Type
BACKGROUND
Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011 Aug;36(8):829-34. doi: 10.1016/j.addbeh.2011.03.013. Epub 2011 Mar 25.
Reference Type
BACKGROUND
Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23. doi: 10.3109/00952990.2011.596982.
Reference Type
BACKGROUND
Najavits LM, Weiss RD, Shaw SR. The link between substance abuse and posttraumatic stress disorder in women. A research review. Am J Addict. 1997 Fall;6(4):273-83.
Reference Type
BACKGROUND
Chander G, McCaul ME. Co-occurring psychiatric disorders in women with addictions. Obstet Gynecol Clin North Am. 2003 Sep;30(3):469-81. doi: 10.1016/s0889-8545(03)00079-2.
Reference Type
BACKGROUND
Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF. Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics. 2003 Mar;111(3):564-72. doi: 10.1542/peds.111.3.564.
Reference Type
BACKGROUND
Heffner JL, Blom TJ, Anthenelli RM. Gender differences in trauma history and symptoms as predictors of relapse to alcohol and drug use. Am J Addict. 2011 Jul-Aug;20(4):307-11. doi: 10.1111/j.1521-0391.2011.00141.x. Epub 2011 May 31.
Reference Type
BACKGROUND
Seng JS, D'Andrea W, Ford JD. Complex Mental Health Sequelae of Psychological Trauma Among Women in Prenatal Care. Psychol Trauma. 2014 Jan;6(1):41-49. doi: 10.1037/a0031467.
Reference Type
BACKGROUND
Simpson TL, Miller WR. Concomitance between childhood sexual and physical abuse and substance use problems. A review. Clin Psychol Rev. 2002 Feb;22(1):27-77. doi: 10.1016/s0272-7358(00)00088-x.
Reference Type
BACKGROUND
Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Fischer G, Jones HE, Martin PR. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010 Sep-Oct;19(5):416-21. doi: 10.1111/j.1521-0391.2010.00064.x.
Reference Type
BACKGROUND
Jones HE, Svikis D, Rosado J, Tuten M, Kulstad JL. What if they do not want treatment?: lessons learned from intervention studies of non-treatment-seeking, drug-using pregnant women. Am J Addict. 2004 Jul-Sep;13(4):342-57. doi: 10.1080/10550490490483008.
Reference Type
BACKGROUND
Thompson MP, Kingree JB. The frequency and impact of violent trauma among pregnant substance abusers. Addict Behav. 1998 Mar-Apr;23(2):257-62. doi: 10.1016/s0306-4603(97)00032-4.
Reference Type
BACKGROUND
Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat. 2007 Jan;32(1):19-25. doi: 10.1016/j.jsat.2006.06.015. Epub 2006 Oct 13.
Reference Type
BACKGROUND
Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35(5):358-63. doi: 10.1080/00952990903108231.
Reference Type
BACKGROUND
Benningfield MM, Dietrich MS, Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Fischer G, Martin PR. Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction. 2012 Nov;107 Suppl 1(0 1):74-82. doi: 10.1111/j.1360-0443.2012.04041.x.
Reference Type
BACKGROUND
Ashley OS, Marsden ME, Brady TM. Effectiveness of substance abuse treatment programming for women: a review. Am J Drug Alcohol Abuse. 2003;29(1):19-53. doi: 10.1081/ada-120018838.
Reference Type
BACKGROUND
Flavin J, Paltrow LM. Punishing pregnant drug-using women: defying law, medicine, and common sense. J Addict Dis. 2010 Apr;29(2):231-44. doi: 10.1080/10550881003684830.
Reference Type
BACKGROUND
Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder--and its treatment. JAMA. 2014 Apr 9;311(14):1393-4. doi: 10.1001/jama.2014.2147. No abstract available.
Reference Type
BACKGROUND
Schroedel JR, Fiber P. Punitive versus public health oriented responses to drug use by pregnant women. Yale J Health Policy Law Ethics. 2001 Spring;1:217-35. No abstract available.
Reference Type
BACKGROUND
Jansson LM, Svikis D, Lee J, Paluzzi P, Rutigliano P, Hackerman F. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat. 1996 Jul-Aug;13(4):321-9. doi: 10.1016/s0740-5472(96)00070-0.
Reference Type
BACKGROUND
Shaw MR, Lederhos C, Haberman M, Howell D, Fleming S, Roll J. Nurses' Perceptions of Caring for Childbearing Women who Misuse Opioids. MCN Am J Matern Child Nurs. 2016 Jan-Feb;41(1):37-42. doi: 10.1097/NMC.0000000000000208.
Reference Type
BACKGROUND
Friedrichs A, Spies M, Harter M, Buchholz A. Patient Preferences and Shared Decision Making in the Treatment of Substance Use Disorders: A Systematic Review of the Literature. PLoS One. 2016 Jan 5;11(1):e0145817. doi: 10.1371/journal.pone.0145817. eCollection 2016.
Reference Type
BACKGROUND
Brener L, Resnick I, Ellard J, Treloar C, Bryant J. Exploring the role of consumer participation in drug treatment. Drug Alcohol Depend. 2009 Nov 1;105(1-2):172-5. doi: 10.1016/j.drugalcdep.2009.06.016. Epub 2009 Jul 21.
Reference Type
BACKGROUND
Simpatico TA. Vermont responds to its opioid crisis. Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.
Reference Type
BACKGROUND
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9;307(18):1934-40. doi: 10.1001/jama.2012.3951. Epub 2012 Apr 30.
Reference Type
BACKGROUND
Jumah NA. Rural, Pregnant, and Opioid Dependent: A Systematic Review. Subst Abuse. 2016 Jun 20;10(Suppl 1):35-41. doi: 10.4137/SART.S34547. eCollection 2016.
Reference Type
BACKGROUND
Oetzel JG, Zhou C, Duran B, Pearson C, Magarati M, Lucero J, Wallerstein N, Villegas M. Establishing the psychometric properties of constructs in a community-based participatory research conceptual model. Am J Health Promot. 2015 May-Jun;29(5):e188-202. doi: 10.4278/ajhp.130731-QUAN-398. Epub 2014 Apr 10.
Reference Type
BACKGROUND
Oetzel JG, Villegas M, Zenone H, White Hat ER, Wallerstein N, Duran B. Enhancing stewardship of community-engaged research through governance. Am J Public Health. 2015 Jun;105(6):1161-7. doi: 10.2105/AJPH.2014.302457. Epub 2015 Apr 16.
Reference Type
BACKGROUND
Wallerstein NB, Duran B. Using community-based participatory research to address health disparities. Health Promot Pract. 2006 Jul;7(3):312-23. doi: 10.1177/1524839906289376. Epub 2006 Jun 7.
Reference Type
BACKGROUND
Sandoval JA, Lucero J, Oetzel J, Avila M, Belone L, Mau M, Pearson C, Tafoya G, Duran B, Iglesias Rios L, Wallerstein N. Process and outcome constructs for evaluating community-based participatory research projects: a matrix of existing measures. Health Educ Res. 2012 Aug;27(4):680-90. doi: 10.1093/her/cyr087. Epub 2011 Sep 21.
Reference Type
BACKGROUND
Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorders treatment. Psychol Addict Behav. 2011 Jun;25(2):194-205. doi: 10.1037/a0022284.
Reference Type
BACKGROUND
Hesselink G, Johnson J, Batalden P, Carlson M, Geense W, Groenewoud S, Jones S, Roy B, Sansone C, Wolf JRLM, Bart B, Wollersheim H. 'Reframing Healthcare Services through the Lens of Co-Production' (RheLaunCh): a study protocol for a mixed methods evaluation of mechanisms by which healthcare and social services impact the health and well-being of patients with COPD and CHF in the USA and The Netherlands. BMJ Open. 2017 Sep 7;7(9):e017292. doi: 10.1136/bmjopen-2017-017292.
Reference Type
BACKGROUND
Portela MC, Pronovost PJ, Woodcock T, Carter P, Dixon-Woods M. How to study improvement interventions: a brief overview of possible study types. BMJ Qual Saf. 2015 May;24(5):325-36. doi: 10.1136/bmjqs-2014-003620. Epub 2015 Mar 25.
Reference Type
BACKGROUND
Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000 Sep;11(5):550-60. doi: 10.1097/00001648-200009000-00011.
Reference Type
BACKGROUND
Westfall PH, Tobias RD, Wolfinger RD. Multiple comparisons and multiple tests using SAS. Cary, N.C.: SAS Pub.; 2011
Reference Type
BACKGROUND
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.
Reference Type
BACKGROUND
Stuart EA, Marcus SM, Horvitz-Lennon MV, Gibbons RD, Normand SL. Using Non-experimental Data to Estimate Treatment Effects. Psychiatr Ann. 2009 Jul 1;39(7):41451. doi: 10.3928/00485713-20090625-07.
Reference Type
BACKGROUND
Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011 May;46(3):399-424. doi: 10.1080/00273171.2011.568786. Epub 2011 Jun 8.
Reference Type
BACKGROUND
Lee J, Little TD. A practical guide to propensity score analysis for applied clinical research. Behav Res Ther. 2017 Nov;98:76-90. doi: 10.1016/j.brat.2017.01.005. Epub 2017 Jan 19.
Reference Type
BACKGROUND
Hedeker DR, Gibbons RD. Wiley Series in Probability and Statistics: Longitudinal Data Analysis. 2006. ISBN-13: 978-0471420279
Reference Type
BACKGROUND
Molenberghs G, Kenward MG. Missing Data in Clinical Studies. Chichester: Wiley; 2007. ISBN: 978-0-470-84981-1
Reference Type
BACKGROUND
Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol. 2013 Aug;66(8):818-25. doi: 10.1016/j.jclinepi.2013.02.009. Epub 2013 May 4.
Reference Type
BACKGROUND
Lagakos SW. The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006 Apr 20;354(16):1667-9. doi: 10.1056/NEJMp068070. No abstract available.
Reference Type
BACKGROUND
Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005 Nov;15(9):1277-88. doi: 10.1177/1049732305276687.
Reference Type
BACKGROUND
Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015 Aug;35(8):650-5. doi: 10.1038/jp.2015.36. Epub 2015 Apr 30.
Reference Type
BACKGROUND
Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann Fam Med. 2004 May-Jun;2(3):204-8. doi: 10.1370/afm.141.
Reference Type
BACKGROUND
McHugo GJ, Drake RE, Whitley R, Bond GR, Campbell K, Rapp CA, Goldman HH, Lutz WJ, Finnerty MT. Fidelity outcomes in the National Implementing Evidence-Based Practices Project. Psychiatr Serv. 2007 Oct;58(10):1279-84. doi: 10.1176/ps.2007.58.10.1279.
Reference Type
BACKGROUND
Patrick SW, Dudley J, Martin PR, Harrell FE, Warren MD, Hartmann KE, Ely EW, Grijalva CG, Cooper WO. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015 May;135(5):842-50. doi: 10.1542/peds.2014-3299. Epub 2015 Apr 13.
Reference Type
BACKGROUND
Ordean A, Kahan M, Graves L, Abrahams R, Kim T. Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study. J Obstet Gynaecol Can. 2015 Mar;37(3):252-257. doi: 10.1016/S1701-2163(15)30311-X.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.maine.gov/tools/whatsnew/index.php?topic=Portal+News&id=726499&v=article-2016
Maine Department of Health and Human Services (DHHS): DHHS to announce the expansion of Medication Assisted Treatment services statewide
https://www.acog.org/About-ACOG/ACOG-Departments/ACOG-Rounds/April-2016/Responding-to-a-National-Crisis-Opioid-Trainings-and-Clinical-Guidance
American College of Obstetricians and Gynecologists. Medical Education: Responding to a national crisis: Opioid Trainings and Clinical Guidance
https://www.healthinsurance.org/maine-medicaid/
Norris L. Maine and Affordable Care Act's (ACA) Medicaid Expansion. 2017
https://www.kff.org/medicaid/state-indicator/delivery-system-reform-incentive-payment-program-dsrip-waivers-and-uncompensated-care-pools-in-place/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
The Henry J. Kaiser Family Foundation. Delivery System Reform Incentive Payment Program (DSRIP) Waivers in Place. 2017
https://www.samhsa.gov/data/sites/default/files/2015_National_Barometer.pdf
Substance Use and Mental Health Services Administration. Behavioral Health Barometer: United States, 2015. Rockville, Maryland: Substance Abuse and Mental Health Services Administration, 2015
http://www.healthvermont.gov/sites/default/files/documents/2016/12/ADAP_Opioids_Prevalence_Risk_Impact.pdf
Vandonsel A, Livingston, S., Searle, J. Opioids in Vermont: Prevalence, use, and impact. Vermont Department of Health, 2016
http://www.vdh.virginia.gov/content/uploads/sites/18/2016/04/Final-Pregnancy-Associated-Deaths-Due-to-Drug-Overdose.pdf
Maternal Mortality Review Team. Richmond, Virginia: Virginia Department of Health;2015
https://www.acog.org/About-ACOG/News-Room/Statements/2016/ACOG-Statement-on-Opioid-Use-During-Pregnancy
American College of Obstetrics and Gynecologists. Statement on Opioid Use During Pregnancy. May 26, 2016
https://ncsacw.samhsa.gov/files/Collaborative_Approach_508.pdf
Substance Use and Mental Health Services Administration. A collaborative approach to the treatment of women with opioid use disorders. Rockville, Maryland: Substance Abuse and Mental Health Services Administration; 2016
https://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/
World Health Organization Guidelines Review Committee. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. World Health Organization 2014
https://www.acog.org/About-ACOG/News-Room/Statements/2016/ACOG-Statement-on-Opioid-Use-During-Pregnancy?IsMobileSet=false
The American College of Obstetricians and Gynecologists Statement on Opioid Use During Pregnancy. May 26, 2016
https://doi.org/10.1186/s40352-015-0015-5
Stone R. Pregnant women and substance use: fear, stigma, and barriers to care. Health Justice. 2015;3(1)
https://www.ncbi.nlm.nih.gov/books/NBK126190/
Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds. Developing a Protocol for Observational Comparative Effectiveness Research. Washington, DC: United States Department of Health and Human Services; 2013. AHRQ, ed.
https://www.sas.com/en_us/software/sas9.html
SAS Institute Inc. SAS/STAT User's Guide, version 9.4. Cary, NC: SAS Institute Inc.; 2015
https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-methodology-standards
Patient Centered Outcomes Research Institute Methodology Committee. PCORI Methodology Standards. Washington, DC, 2017
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00031444
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20
NCT00000238
COMPLETED
PHASE2
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
NCT01052662
COMPLETED
PHASE2/PHASE3
Enhancing Recovery Capital Amid Opioid Use Disorder Pharmacotherapy: A Pilot Randomized Trial
NCT05245513
NOT_YET_RECRUITING
NA
Prevention Interventions for Opioid Misuse
NCT04550715
COMPLETED
NA
Reducing Non-Medical Opioid Use: An Automatically Adaptive mHealth Intervention
NCT02990377
COMPLETED
NA
Response to Relapse in Office-Based Opioid Treatment Trial
NCT03812107
TERMINATED
NA
Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
NCT02411357
COMPLETED
NA
Serving Women Using Opioids During Pregnancy
NCT03552120
TERMINATED
NA
Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
NCT05047627
COMPLETED
NA
Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
NCT00522626
COMPLETED
Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment
NCT07197801
RECRUITING
NA
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
NCT03911466
COMPLETED
PHASE3
Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons
NCT06999811
RECRUITING
NA
Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22
NCT00000240
COMPLETED
PHASE2
On-site Evaluation of Substances Consumption on Opiate Maintenance
NCT02345655
COMPLETED
NA
Opioid Treatment and Peer Recovery Support
NCT04978168
RECRUITING
NA
Harnessing Digital Health to Understand Clinical Trajectories of Opioid Use Disorder
NCT04535583
COMPLETED
Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum Period
NCT04939012
RECRUITING
NA
Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0
NCT04939727
COMPLETED
NA
Treatment of Pregnant Women With OUD
NCT04240392
COMPLETED
NA
Safety and Health Intervention Project
NCT02152397
COMPLETED
NA
Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department
NCT07129902
NOT_YET_RECRUITING
NA
Following Outcomes Remotely Within Addiction Recovery Domains
NCT06001437
RECRUITING
Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With OUD
NCT05817825
RECRUITING
NA
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
NCT05973838
RECRUITING
NA